Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration
2007-006093-28Phase 3Active
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de Getafe
- Start
- Dec 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Bevacizumab intravitreal with Ranibizumab intravitreal (2 arms). Primary endpoints: Efficacy criteria and Safety. Started Dec 2007; status: active.
02
Drugs
bevacizumabranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-006093-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006093-28.